<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03281863</url>
  </required_header>
  <id_info>
    <org_study_id>AssiutU71516</org_study_id>
    <nct_id>NCT03281863</nct_id>
  </id_info>
  <brief_title>Clinical Audit on the Managment in Assiut University Children Hospital</brief_title>
  <official_title>Clinical Audit on the Managment of Rheumatic Fever in Assiut University Children Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      clinical audit on the Managment of rheumatic fever in assiut university children hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute rheumatic fever,an auto immune response to Group A streptococcus infection of the upper&#xD;
      respiratory tract,may result in carditis.when the inflammation leads to permenant damage of&#xD;
      the valves the individual has rheumatic heart disease.&#xD;
&#xD;
      Recurrences of rheumatic fever are likely in the absence of preventive measures and may cause&#xD;
      further cardiac valve and muscle damage,leading to heart failure,stroke and premature&#xD;
      death.bacterial endocarditis is also a complication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">March 24, 2020</completion_date>
  <primary_completion_date type="Actual">March 24, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>laboratory investigations (ASOt , ESR . CRP)</measure>
    <time_frame>One year from October 2017 to september 2018</time_frame>
    <description>laboratory investigations that measure the inflammation process will be used and the target that the ASOt not increase 1/400</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical measures</measure>
    <time_frame>One year from October 2017 to september 2018</time_frame>
    <description>improvement of arthritis if found</description>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Rheumatic Fever</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>C reactive protein, anti streptolysin o antibody test ,erythrocyte sedimentation rate</intervention_name>
    <description>Throat culture to detect the causative organism</description>
    <other_name>Throat culture</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Clinical audit on the managment of rheumatic fever in assiut university children hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with confirmed diagnosis of rheumatic fever based on laboratory&#xD;
             investigations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Egypt</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 29, 2017</study_first_submitted>
  <study_first_submitted_qc>September 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2017</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Patricia reda hanna</investigator_full_name>
    <investigator_title>Resident doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Fever</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antistreptolysin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

